What is the value of Seeing Machines' new contract?

The contract is worth approximately $5 million in estimated lifetime revenue.

What grant did Frontier IP's portfolio company receive?

Cambridge Raman Imaging secured a €400,000 European grant to scale up its pharmaceutical quality control technology.

What is Thermo Fisher's role in the ImmuPharma partnership?

Thermo Fisher will develop and manufacture the finished form of the diabetes drug Kapiglucagon.

What was MP Evans' palm oil production in the first half?

Crude palm oil production reached 192,300 tonnes, up 11% year-on-year.

When is 88 Energy expected to spud its Alaska well?

The spud is expected in the first quarter of 2027.

Small Cap Snapshot: Seeing Machines, Frontier IP, ImmuPharma, MP Evans, Ariana Resources, 88 Energy

Several AIM-listed small caps announced key developments: Seeing Machines secured a $5 million driver monitoring contract, Frontier IP's portfolio company won a €400,000 grant, ImmuPharma appointed Thermo Fisher for diabetes drug manufacturing, and MP Evans saw palm oil production rise 11%.

Overview

Several small-cap companies listed on London's AIM market reported significant developments this week, including new contracts, grants, strategic partnerships, and production milestones.

Seeing Machines: New Contract with European Carmaker

Seeing Machines (AIM:SEE) announced it has won a new driver monitoring contract with a European carmaker, with estimated lifetime revenues of approximately $5 million. The contract comes as new EU safety regulations make the technology mandatory on new vehicles. Production is scheduled to begin in 2028, with the system integrated into a rear-view mirror for easy deployment across multiple platforms.

Frontier IP: European Grant for Portfolio Company

Frontier IP (LSE:FIPP) said its portfolio company Cambridge Raman Imaging has secured a €400,000 European grant to scale up its AI-powered pharmaceutical quality control technology. The company has also appointed a China-based distributor with over 100 customers globally.

ImmuPharma: Thermo Fisher Partnership

ImmuPharma (AIM:IMM) has appointed Thermo Fisher Scientific to develop and manufacture the finished form of its experimental diabetes treatment Kapiglucagon. This completes the main manufacturing partnerships alongside Swiss group Bachem, which is handling the active ingredient.

MP Evans: Palm Oil Production Growth

MP Evans (AIM:MPE) reported an 11% increase in crude palm oil production to 192,300 tonnes in the first half, supported by higher harvests across its Indonesian estates. Pricing remained firm at around $873 per tonne.

Ariana Resources: Ramp-Up Complete at Turkish Gold Mine

Ariana Resources (AIM:AAU) said its Tavşan gold mine in Türkiye has completed its ramp-up and is now processing ore at the required rate of at least 4,000 tonnes per day. Gold recovery is tracking at around 70%.

88 Energy: Alaska Well Progress

88 Energy (AIM:88E) has moved its Augusta-1 Alaska well closer to a first-quarter 2027 spud after securing a rig and camp. Prospective resources at South Prudhoe have also been upgraded by 35%.